{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:36:37Z","timestamp":1789799797592,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>There are scenarios where pre-mixing and infusing analgesic and anaesthetic agents as a single intravenous (IV) solution is highly desirable; however, it is important to ensure the agents are compatible when mixed. As such, the long-term stability of a remifentanil-propofol mixture, and means of improving this, were assessed across a range of remifentanil concentrations, diluents, and time points.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Remifentanil was reconstituted with ultrapure water, 0.9% saline, 20% saline, or 8.4% sodium bicarbonate solution (the latter two chosen for their pH characteristics, rather than their use in pharmaceutical reconstitution) and then mixed with propofol (1%) or further diluted with water to derive concentrations of 10\u201350\u2009\u03bcg\u2009mL<jats:sup>\u2212\u20091<\/jats:sup>. Remifentanil and propofol concentrations were determined initially and then periodically for up to 24\u2009h using high performance liquid chromatography (HPLC). Mass spectrometry (MS) was used to detect degradation products in solutions containing 30\u2009\u03bcg\u2009mL<jats:sup>\u2212\u20091<\/jats:sup> of remifentanil. Statistical analysis was performed using ANOVA and Student\u2019s <jats:italic>t<\/jats:italic>-test, with a significance value of 0.05.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Isolated remifentanil (pH &lt;\u20094) and propofol (pH\u20097.35) did not degrade significantly when reconstituted with water or saline solution over 24\u2009h, while remifentanil reconstituted with sodium bicarbonate degraded significantly (<jats:italic>P<\/jats:italic>\u00a0&lt;\u20090.001, pH\u20098.65). Mixing with propofol substantially increased the pH of the mixture and resulted in significant remifentanil degradation for all reconstitution solutions used, while propofol remained stable (pH\u20096.50). The amount of degradation product detected in samples containing isolated remifentanil and a mixture of the drugs was proportional to the remifentanil degradation observed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Remifentanil stability is affected by both the reconstitution solution used and when mixed with propofol, with pH appearing to be a contributing factor to degradation. If the pH of the solution and concentration of remifentanil are correctly controlled, e.g. through the use of a more acidic diluent, an admixture of remifentanil and propofol may be useful clinically.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12871-020-01194-5","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T17:05:36Z","timestamp":1605200736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-1378","authenticated-orcid":false,"given":"Emily","family":"Henkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Behan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"issue":"1","key":"1194_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00023210-199911010-00002","volume":"11","author":"NR Gravel","year":"1999","unstructured":"Gravel NR, Searle NR, Sahab PG, Carrier M. Sedation in critically ill patients: practical recommendations. CNS Drugs. 1999 Jan;11(1):9\u201322. https:\/\/doi.org\/10.2165\/00023210-199911010-00002.","journal-title":"CNS Drugs"},{"issue":"5","key":"1194_CR2","first-page":"1","volume":"14","author":"S Pinkney","year":"2014","unstructured":"Pinkney S, Fan M, Chan K, Koczmara C, Colvin C, Sasangohar F, et al. Multiple intravenous infusions phase 2b: laboratory study. Ont Health Technol Assess Ser. 2014;14(5):1\u2013163.","journal-title":"Ont Health Technol Assess Ser."},{"issue":"16","key":"1194_CR3","first-page":"1","volume":"12","author":"A Cassano-Pich\u00e9","year":"2012","unstructured":"Cassano-Pich\u00e9 A, Fan M, Sabovitch S, Masino C, Easty AC. Health technology safety research team, et al. multiple intravenous infusions phase 1b: practice and training scan. Ont Health Technol Assess Ser. 2012;12(16):1\u2013132.","journal-title":"Ont Health Technol Assess Ser"},{"issue":"3","key":"1194_CR4","first-page":"207","volume":"73","author":"WJ Brady","year":"2005","unstructured":"Brady WJ, Meenan DR, Shankar TR, Balon JA, Mennett DR. Use of a remifentanil and propofol combination in outpatients to facilitate rapid discharge home. AANA J. 2005;73(3):207\u201310.","journal-title":"AANA J"},{"issue":"1","key":"1194_CR5","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1213\/ane.0000000000003772","volume":"129","author":"P Bedocs","year":"2019","unstructured":"Bedocs P, Evers DL, Buckenmaier CC III. Predosing chemical stability of admixtures of propofol, ketamine, fentanyl, and remifentanil. Anesth Analg. 2019;129(1):e13\u20135. https:\/\/doi.org\/10.1213\/ane.0000000000003772.","journal-title":"Anesth Analg"},{"issue":"5","key":"1194_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/00000539-200211000-00038","volume":"95","author":"PJ Davis","year":"2002","unstructured":"Davis PJ, Stiller RL, Wilson AS, McGowan FX, Egan TD, Muir KT. In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase. Anesth Analg. 2002;95(5):1305\u20137. https:\/\/doi.org\/10.1097\/00000539-200211000-00038.","journal-title":"Anesth Analg"},{"key":"1194_CR7","doi-asserted-by":"publisher","unstructured":"Said R, Pohanka A, Andersson M, Beck O, Abdel-Rehim M. Determination of remifentanil in human plasma by liquid chromatography-tandem mass spectrometry utilizing micro extraction in packed syringe (MEPS) as sample preparation. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(11\u201312):815\u20138. https:\/\/doi.org\/10.1016\/j.jchromb.2011.02.002.","DOI":"10.1016\/j.jchromb.2011.02.002"},{"issue":"2","key":"1194_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00000542-200002000-00020","volume":"92","author":"HD Babenco","year":"2000","unstructured":"Babenco HD, Conard PF, Gross JB. The pharmacodynamic effect of a remifentanil bolus on ventilatory control. Anesthesiology. 2000;92(2):393\u20138. https:\/\/doi.org\/10.1097\/00000542-200002000-00020.","journal-title":"Anesthesiology."},{"issue":"4","key":"1194_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/bja\/aeh086","volume":"92","author":"M Pitsiu","year":"2004","unstructured":"Pitsiu M, Wilmer A, Bodenham A, Breen D, Bach V, Bonde J, et al. Pharmacokinetics of remifentanil and its major metabolite remifentanil acid, in ICU patients with renal impairment. Br J Anaesth. 2004;92(4):493\u2013503. https:\/\/doi.org\/10.1093\/bja\/aeh086.","journal-title":"Br J Anaesth"},{"issue":"2","key":"1194_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2165\/00003088-199529020-00003","volume":"29","author":"TD Egan","year":"1995","unstructured":"Egan TD. Remifentanil pharmacokinetics and pharmacodynamics: a preliminary appraisal. Clin Pharmacokinet. 1995;29(2):80\u201394. https:\/\/doi.org\/10.2165\/00003088-199529020-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1194_CR11","doi-asserted-by":"publisher","first-page":"6852857","DOI":"10.1155\/2018\/6852857","volume":"2018","author":"RJ Dinis-Oliveira","year":"2018","unstructured":"Dinis-Oliveira RJ. Metabolic profiles of propofol and fospropofol: clinical and forensic interpretative aspects. Biomed Res Int. 2018;2018:6852857. https:\/\/doi.org\/10.1155\/2018\/6852857.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1194_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/0929867003375335","volume":"7","author":"G Trapani","year":"2000","unstructured":"Trapani G, Altomare C, Liso G, Sanna E, Biggio G. Propofol in anaesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem. 2000;7(2):249\u201371. https:\/\/doi.org\/10.2174\/0929867003375335.","journal-title":"Curr Med Chem"},{"issue":"2","key":"1194_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00000542-200308000-00016","volume":"99","author":"MJ Mertens","year":"2003","unstructured":"Mertens MJ, Olofsen E, Engbers FHM, Burm AGL, Bovill JG, Vuyk J. Propofol reduces perioperative remifentanil requirements in a synergistic manner: response surface modelling of perioperative remifentanil-propofol interactions. Anesthesiology. 2003;99(2):347\u201359.","journal-title":"Anesthesiology."},{"issue":"3","key":"1194_CR14","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/cc4939","volume":"10","author":"B Muellejans","year":"2006","unstructured":"Muellejans B, Matthey T, Scholpp J, Schill M. Sedation in the intensive care unit with remifentanil\/propofol versus midazolam\/fentanyl: a randomised, open-label, pharmacoeconomic trial. Crit Care. 2006;10(3):R91\u20139. https:\/\/doi.org\/10.1186\/cc4939.","journal-title":"Crit Care"},{"key":"1194_CR15","unstructured":"U.S. National Library of Medicine. Use of a remifentanil-propofol mixture in patients undergoing breast cancer surgery. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03817359; 2019. Accessed 23 Mar 2019."},{"issue":"1","key":"1194_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4103\/0970-9185.125725","volume":"30","author":"BG Goudra","year":"2014","unstructured":"Goudra BG, Singh PM, Sinha A. Providing anesthesia in a remote location for radiation oncology in an adult \u2013 problems and solutions. J Anaesthesiol Clin Pharmacol. 2014;30(1):114\u20136. https:\/\/doi.org\/10.4103\/0970-9185.125725.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"3","key":"1194_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2344\/12-00001.1","volume":"59","author":"KJ Kramer","year":"2012","unstructured":"Kramer KJ, Ganzberg S, Prior S, Rashid RG. Comparison of propofol-remifentanil versus propofol-ketamine deep sedation for third molar surgery. Anesth Prog. 2012;59(3):107\u201317. https:\/\/doi.org\/10.2344\/12-00001.1.","journal-title":"Anesth Prog"},{"issue":"11","key":"1194_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1460-9592.2004.01355.x","volume":"14","author":"JW Berkenbosch","year":"2004","unstructured":"Berkenbosch JW, Graff GR, Stark JM, Ner Z, Tobias JD. Use of a remifentanil-propofol mixture for pediatric flexible fiberoptic bronchoscopy sedation. Pediatr Anesth. 2004;14(11):941\u20136. https:\/\/doi.org\/10.1111\/j.1460-9592.2004.01355.x.","journal-title":"Pediatr Anesth"},{"issue":"5","key":"1194_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1460-9592.2005.01462.x","volume":"15","author":"BCH Tsui","year":"2005","unstructured":"Tsui BCH, Wagner A, Usher AG, Cave DA, Tang C. Combined propofol and remifentanil intravenous anesthesia for pediatric patients undergoing magnetic resonance imaging. Pediatr Anesth. 2005;15(5):397\u2013401. https:\/\/doi.org\/10.1111\/j.1460-9592.2005.01462.x.","journal-title":"Pediatr Anesth"},{"issue":"5","key":"1194_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jclinane.2007.02.005","volume":"19","author":"TZ Apan","year":"2007","unstructured":"Apan TZ, Apan A, \u015eahin S, \u00c7ak\u0131rca M. Antibacterial activity of remifentanil and mixtures of remifentanil and propofol. J Clin Anesth. 2007;19(5):346\u201350. https:\/\/doi.org\/10.1016\/j.jclinane.2007.02.005.","journal-title":"J Clin Anesth"},{"issue":"6","key":"1194_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.bjane.2012.10.003","volume":"63","author":"IA Erden","year":"2013","unstructured":"Erden IA, G\u00fclmez D, Pamuk AG, Akincia SB, Has\u00e7elik G, Aypar U. The growth of bacteria in infusion drugs: propofol 2% supports growth when remifentanil and pantoprazole do not. Rev Bras Anestesiol. 2013 Nov-Dec;63(6):466\u201372. https:\/\/doi.org\/10.1016\/j.bjane.2012.10.003.","journal-title":"Rev Bras Anestesiol"},{"issue":"6","key":"1194_CR22","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/00000539-200006000-00037","volume":"90","author":"JT Stewart","year":"2000","unstructured":"Stewart JT, Warren FW, Maddox FC, Vishwanathan K, Fox JL. The stability of remifentanil hydrochloride and propofol mixtures in polypropylene syringes and polyvinylchloride bags at 22\u00b0 - 24\u00b0C. Anesth Analg. 2000;90(6):1450\u20131. https:\/\/doi.org\/10.1097\/00000539-200006000-00037.","journal-title":"Anesth Analg"},{"issue":"5","key":"1194_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/ejhpharm-2016-001038","volume":"24","author":"F Gersonde","year":"2017","unstructured":"Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. Eur J Hosp Pharm. 2017;24(5):293\u2013303. https:\/\/doi.org\/10.1136\/ejhpharm-2016-001038.","journal-title":"Eur J Hosp Pharm"},{"issue":"7","key":"1194_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/0952-8180(95)00127-1","volume":"7","author":"PSA Glass","year":"1995","unstructured":"Glass PSA. Remifentanil: a new opioid. J Clin Anesth. 1995;7(7):558\u201363. https:\/\/doi.org\/10.1016\/0952-8180(95)00127-1.","journal-title":"J Clin Anesth"},{"issue":"5","key":"1194_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1046\/j.1365-2044.1998.00405.x","volume":"53","author":"CH Tan","year":"1998","unstructured":"Tan CH, Onsiong MK. Pain on injection of propofol. Anaesthesia. 1998;53(5):468\u201376. https:\/\/doi.org\/10.1046\/j.1365-2044.1998.00405.x.","journal-title":"Anaesthesia."},{"issue":"9","key":"1194_CR26","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3760\/cma.j.issn.0366-6999.2009.09.006","volume":"122","author":"LP Zhang","year":"2009","unstructured":"Zhang LP, Yang L, Bi SS, Lu W, Zhang XH, Zhai SD, et al. Population pharmacokinetics of remifentanil in patients undergoing orthotopic liver transplantation. Chin Med J. 2009;122(9):1032\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.0366-6999.2009.09.006.","journal-title":"Chin Med J"},{"issue":"7","key":"1194_CR27","first-page":"718","volume":"33","author":"SD Zhou","year":"2007","unstructured":"Zhou SD, Lu HW, Xie F, Qin F, Tao GJ. determination of remifentanil concentration in human whole blood by HPLC\/MS. Jiangsu med J. 2007;33(7):718\u201320 Chinese.","journal-title":"Jiangsu med J"},{"issue":"12","key":"1194_CR28","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/0731-7085(96)01831-6","volume":"14","author":"SH Haidar","year":"1996","unstructured":"Haidar SH, Zhongming L, Selinger K, Hamlett L, Eddington ND. Determination of remifentanil, an ultra-short acting opioid anesthetic, in rat blood by high performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal. 1996;14(12):1727\u201332. https:\/\/doi.org\/10.1016\/0731-7085(96)01831-6.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"1194_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0378-4347(98)00466-6","volume":"721","author":"TB Vree","year":"1999","unstructured":"Vree TB, Lagerwerf AJ, Bleeker CP, de Grood PMRM. Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. J Chromatogr B Biomed Sci Appl. 1999;721(2):217\u201328. https:\/\/doi.org\/10.1016\/S0378-4347(98)00466-6.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"3","key":"1194_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jpba.2006.10.020","volume":"44","author":"X Cussonneau","year":"2007","unstructured":"Cussonneau X, De Smet E, Lantsoght K, Salvi JP, Bolon-Larger M, Boulieu R. A rapid and simple HPLC method for the analysis of propofol in biological fluids. J Pharm Biomed Anal. 2007;44(3):680\u20132. https:\/\/doi.org\/10.1016\/j.jpba.2006.10.020.","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"1194_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/pan.12917","volume":"26","author":"S O\u2019Connor","year":"2016","unstructured":"O\u2019Connor S, Zhang YL, Christians U, Morrison JE Jr, Friesen RH. Remifentanil and propofol undergo separation and layering when mixed in the same syringe for total intravenous anesthesia. Pediatr Anesth. 2016;26(7):703\u20139. https:\/\/doi.org\/10.1111\/pan.12917.","journal-title":"Pediatr Anesth"},{"issue":"4","key":"1194_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/00000542-200510000-00026","volume":"103","author":"MT Baker","year":"2005","unstructured":"Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005;103(4):860\u201376.","journal-title":"Anesthesiology."},{"issue":"2","key":"1194_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/bjaceaccp\/mkm008","volume":"7","author":"A Pai","year":"2007","unstructured":"Pai A, Heining M. Ketamine. Contin Educ in Anaesth, Crit Care & Pain. 2007;7(2):59\u201363. https:\/\/doi.org\/10.1093\/bjaceaccp\/mkm008.","journal-title":"Contin Educ in Anaesth, Crit Care & Pain"},{"key":"1194_CR34","volume-title":"\u2018Stable formulations of remifentanil\u2019, US patent 5866591, filed 11 September 1996","author":"Glaxo Wellcome Inc","year":"1996","unstructured":"Glaxo Wellcome Inc 1996, \u2018Stable formulations of remifentanil\u2019, US patent 5866591, filed 11 September 1996."},{"issue":"5","key":"1194_CR35","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/00000542-199311000-00005","volume":"79","author":"CL Westmoreland","year":"1993","unstructured":"Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its metabolite (GI90291) in patients undergoing elective impatient surgery. Anesthesiology. 1993;79(5):893\u2013903. https:\/\/doi.org\/10.1097\/00000542-199311000-00005.","journal-title":"Anesthesiology."},{"issue":"4","key":"1194_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1255\/ejms.761","volume":"11","author":"M Thevis","year":"2005","unstructured":"Thevis M, Geyer H, Bahr D, Sch\u00e4nzer W. Identification of fentanyl, alfentanil, sufentanil, remifentanil and their major metabolites in human urine by liquid chromatography\/tandem mass spectrometry for doping control purposes. Eur J Mass Spectrom (Chichester). 2005;11(4):419\u201327. https:\/\/doi.org\/10.1255\/ejms.761.","journal-title":"Eur J Mass Spectrom (Chichester)"},{"issue":"1","key":"1194_CR37","first-page":"226","volume":"281","author":"JF Hoke","year":"1997","unstructured":"Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther. 1997;281(1):226\u201332.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1194_CR38","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1186\/cc2399","volume":"8","author":"D Breen","year":"2004","unstructured":"Breen D, Wilmer A, Bodenham A, Bach V, Bonde J, Kessler P, et al. Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care. 2004 Feb;8(1):R21\u201330. https:\/\/doi.org\/10.1186\/cc2399.","journal-title":"Crit Care"},{"issue":"1","key":"1194_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jclinane.2009.04.003","volume":"22","author":"T Alston","year":"2010","unstructured":"Alston T. Atracurium-like decomposition of remifentanil. J Clin Anesth. 2010;22(1):72\u20133. https:\/\/doi.org\/10.1016\/j.jclinane.2009.04.003.","journal-title":"J Clin Anesth"},{"issue":"4","key":"1194_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jfda.2013.09.006","volume":"21","author":"LJ Wei","year":"2013","unstructured":"Wei LJ, Yu HY, Chang WB, Lin CH, Chen YC, Wu JB. Effect of container on the physicochemical stability of propofol injectable emulsion after being diluted with 0.9% NaCl for intravenous infusion. J Food Drug Anal. 2013;21(4):421\u20135. https:\/\/doi.org\/10.1016\/j.jfda.2013.09.006.","journal-title":"J Food Drug Anal"},{"issue":"2","key":"1194_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1691\/ph.2008.8161","volume":"64","author":"K Nemec","year":"2009","unstructured":"Nemec K, Germ E, Schulz-Siegmund M, Ortner A. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions. Pharmazie. 2009;64(2):94\u20137. https:\/\/doi.org\/10.1691\/ph.2008.8161.","journal-title":"Pharmazie."},{"issue":"3","key":"1194_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4103\/1658-354X.84102","volume":"5","author":"S Aggarwal","year":"2011","unstructured":"Aggarwal S, Kumar M, Sharma V. A single-Centre randomized-controlled trial to study effect of dilution on propofol-induced injection pain at injection site. Saudi J Anaesth. 2011;5(3):282\u20135. https:\/\/doi.org\/10.4103\/1658-354X.84102.","journal-title":"Saudi J Anaesth"},{"issue":"5","key":"1194_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2044.1990.tb14813.x","volume":"45","author":"E Wright","year":"1990","unstructured":"Wright E, Filshie J. Dilution of propofol. Anaesthesia. 1990;45(5):421. https:\/\/doi.org\/10.1111\/j.1365-2044.1990.tb14813.x.","journal-title":"Anaesthesia."},{"issue":"1\u20132","key":"1194_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0378-5173(00)00692-X","volume":"215","author":"J Han","year":"2001","unstructured":"Han J, Davis SS, Washington C. Physical properties and stability of two emulsion formulations of propofol. Int J Pharm. 2001;215(1\u20132):207\u201320. https:\/\/doi.org\/10.1016\/S0378-5173(00)00692-X.","journal-title":"Int J Pharm"},{"issue":"Suppl 1","key":"1194_CR45","doi-asserted-by":"publisher","first-page":"A271","DOI":"10.1136\/ejhpharm-2019-eahpconf.584","volume":"26","author":"N Nilsson","year":"2019","unstructured":"Nilsson N, Nezvalov\u00e1-Henriksen K, Tho I. 5PSQ-151 are propofol emulsions stable when intravenously co-administered with remifentanil? Eur J Hosp Pharm. 2019;26(Suppl 1):A271\u20132. https:\/\/doi.org\/10.1136\/ejhpharm-2019-eahpconf.584.","journal-title":"Eur J Hosp Pharm"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-020-01194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12871-020-01194-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-020-01194-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T17:06:24Z","timestamp":1605200784000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-020-01194-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1186\/s12871-020-01194-5","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"assertion":[{"value":"12 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"283"}}